Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy

A. Jimeno, P. Kulesza, J. Wheelhouse, A. Chan, X. Zhang, E. Kincaid, R. Chen, Douglas Paul Clark, A. Forastiere, Manuel Hidalgo

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma (SCC) of the head and neck. Most patients, however, do not respond or develop resistance to this agent. Mammalian target of rapamycin (mTOR) is involved in the pathogenesis of SCC of the head and neck (SCCHN). This study aimed to determine if targeting mTOR in combination with EGFR is effective in SCC, and to develop early pharmacodynamic markers of efficacy. Two SCC cell lines, one resistant (HEP2) and one of intermediate susceptibility (Detroit 562) to EGFR inhibitors, were xenografted in vivo and treated with an mTOR inhibitor (temsirolimus), an EGFR inhibitor (erlotinib) or a combination of both. Temsirolimus exerted superior growth arrest in both cell lines than erlotinib. The combined treatment resulted in synergistic antitumor effects in the Detroit 562 cell line. Immunohistochemical assessment of pharmacodynamic effects in fine-needle aspiration (FNA) biopsies early after treatment using phospho MAPK, Phospho-P70 and Ki67 as end points demonstrated pathway abrogation in the Detroit 562 tumours treated with the combination, the only group where regressions were seen. In conclusion, an mTOR inhibitor showed antitumor activity in EGFR-resistant SCC cell lines. Marked antitumor effects were associated with dual pathway inhibition, which were detected by early FNA biopsies.

Original languageEnglish (US)
Pages (from-to)952-959
Number of pages8
JournalBritish journal of cancer
Issue number6
StatePublished - Mar 26 2007


  • Dual targeting
  • EGFR
  • Erlotinib
  • Squamous cell carcinoma
  • Temsirolimus
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy'. Together they form a unique fingerprint.

Cite this